Switching to a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates: Results from the multicentre, prospective INTENSIFY study.

Abstract

AIM:

Investigate the effectiveness of IDegLira, a fixed-ratio combination of insulin degludec/liraglutide, in a real-world setting in patients with type 2 diabetes mellitus in the United Arab Emirates.

METHODS:

This non-interventional study enrolled adults switching to IDegLira from basal insulin (BI) or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with/without concomitant oral antidiabetic drugs (OADs). Primary endpoint was change in HbA1c from baseline, assessed using a mixed model for repeated measurements.

RESULTS:

Among 263 patients (BI ± OADs, n = 206; GLP-1 RA ± OADs, n = 57), mean baseline HbA1c was 9.29 % (78 mmol/mol). After 26 weeks, HbA1c was significantly reduced (BI ± OADs, -0.83 % [-9.0 mmol/mol] and GLP-1 RA ± OADs, -1.24 % [-13.5 mmol/mol]; both p < 0.0001). Fasting plasma glucose (FPG) was significantly reduced (-39.48 mg/dL [BI ± OADs] and -82.49 mg/dL [GLP-1 RA ± OADs]; both p < 0.0001). Before treatment initiation, 3/263 patients experienced ≥ 1 severe hypoglycaemic episode and 7/263 patients experienced ≥ 1 non-severe hypoglycaemic episode compared with 1/263 patients who had ≥ 1 severe and 1/263 who had ≥ 1 non-severe episode at end of study. Body weight decreased significantly among patients switching from BI ± OADs (-1.05 kg [p < 0.0001]). Treatment was well tolerated.

CONCLUSIONS:

IDegLira significantly reduced HbA1c and FPG in this real-world setting, along with less frequent episodes of hypoglycaemia. Switching to IDegLira offers effective treatment intensification for type 2 diabetes patients with inadequate glycaemic control.

• Authors: Salah Abusnana, Fatheya Al Awadi, Hazem Aly, Alaaeldin Bashier, Dinesh Kumar Dhanwal, Tariq Halasa, Mahir Jallo, Johan Medina, Sagar Singhal
• Journal: Diabetes research and clinical practice (Diabetes Res Clin Pract) Vol. 196 Pg. 110183 (Feb 2023) ISSN: 1872-8227 [Electronic] Ireland
• PMID: 36436550 (Publication Type: Multicenter Study, Journal Article)
• Copyright: Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.

Chemical References

• IDegLira
• Liraglutide
• insulin degludec
• Glycated Hemoglobin
• Hypoglycemic Agents
• Drug Combinations
• Glucagon-Like Peptide 1
• Blood Glucose

Topics

• Adult
• Humans
• Liraglutide (therapeutic use)
• Diabetes Mellitus, Type 2 (drug therapy)
• Glycated Hemoglobin
• Glycemic Control
• United Arab Emirates
• Prospective Studies
• Hypoglycemic Agents (therapeutic use)
• Drug Combinations
• Hypoglycemia (chemically induced)
• Glucagon-Like Peptide 1 (therapeutic use)
• Blood Glucose